Array BioPharma. (PRNewsFoto/Array BioPharma Inc.)
BOULDER, Colo., Nov. 11, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.
(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)
|
Event: |
Jefferies 2013 Global Healthcare Conference |
|
Date: |
Wednesday, November 20, 2013 |
|
Time: |
8:40 a.m. Greenwich Mean Time |
|
Location: |
London, England |
|
Event: |
Piper Jaffray 25th Annual Healthcare Conference |
|
Date: |
Tuesday, December 3, 2013 |
|
Time: |
3:30 p.m. Eastern Time |
|
Location: |
The New York Palace Hotel, New York City |
About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage oncology development company, with two wholly-owned hematology programs and two partnered MEK inhibitors in multiple pivotal trials. ARRY-520 is a targeted KSP inhibitor being developed to treat patients with multiple myeloma and has demonstrated clinical activity as monotherapy, and in combination with both Kyprolis® (carfilzomib) and Velcade® (bortezomib). ARRY‐614 is an oral p38/Tie2 inhibitor with a novel mechanism of action being developed to treat patients with myelodysplastic syndromes. Both selumetinib, partnered with AstraZeneca, and MEK162, partnered with Novartis, are being studied in several pivotal trials in a variety of solid tumors. For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma
RELATED LINKShttp://www.arraybiopharma.com
| < Prev | Next > |
|---|
